In gastric cancers, CLDN18 has been shown to be reduced [17], while its upregulation has been reported in pre-neoplastic conditions such as Barrett’s esophagus, mucinous cystic neoplasms, and intraductal papillary mucinous neoplasms [156,157,158]. Here, CLDN18 is linked to esophageal adenocarcinoma.